The earnings call highlighted significant clinical and regulatory advancements, successful financing, and positive safety profiles for Ocugen's gene therapy programs. Despite stable operating expenses and cash position, the strategic achievements suggest confidence in Ocugen's future potential.

Company Guidance

During Ocugen's third-quarter earnings call for 2024, significant progress was highlighted across various clinical and operational fronts. The company announced that Health Canada approved the initiation of the OCU400 Phase III-liMeliGhT clinical trial and that the FDA approved an expanded access program for OCU400 for retinitis pigmentosa, aimed at adult patients. Ocugen is actively dosing patients in the OCU410 Phase II ArMaDa trial for geographic atrophy, with a promising safety profile confirmed in the OCU410ST/GARDian trial. Financially, Ocugen reported $39 million in cash as of September 30, 2024, with $14.4 million in operating expenses for the quarter, and secured $30 million through debt financing, extending their runway into Q1 2026. The company also announced plans to initiate a Phase I clinical trial for OCU200, targeting diabetic macular edema. These developments underscore Ocugen's commitment to advancing innovative gene therapies in ophthalmology, with strategic plans for commercialization by 2027.

Clinical and Regulatory Milestones

Ocugen received approval from Health Canada to initiate the OCU400 Phase III clinical trial and approval from the U.S. FDA for an expanded access program for OCU400 to treat adult patients with retinitis pigmentosa.

Successful Debt Financing

Secured $30 million from Avenue Capital Group, extending the financial runway into the first quarter of 2026.

Progress in Gene Therapy Programs

OCU410 and OCU410ST are advancing in clinical trials, with Phase I dosing completed and moving to Phase II for OCU410ST.

OCU200 Phase I Clinical Trial

FDA cleared the investigational drug application for the Phase I clinical trial evaluating OCU200 for diabetic macular edema.

Positive Safety Profiles

OCU410 and OCU410ST demonstrated favorable safety and tolerability profiles, with no serious adverse events reported.

---

Ocugen (OCGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

OCGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 08, 2019	2019 (Q3)	- / -3.55	-14.4	75.35% (+10.85)	―	―
Mar 27, 2020	2019 (Q4)	- / 0.36	-8.65	104.22% (+9.02)	―	―
May 08, 2020	2020 (Q1)	- / -0.07	-7.003	99.00% (+6.93)	―	―
Aug 14, 2020	2020 (Q2)	- / -0.19	-2.048	90.72% (+1.86)	―	―
Nov 06, 2020	2020 (Q3)	- / -0.07	-3.55	98.03% (+3.48)	―	―
Mar 18, 2021	2020 (Q4)	- / -0.02	0.365	-105.48% (-0.39)	―	―
May 07, 2021	2021 (Q1)	0.19 / -0.04	-0.07	42.86% (+0.03)	―	―
Aug 06, 2021	2021 (Q2)	-0.03 / -0.13	-0.19	31.58% (+0.06)	―	―
Nov 09, 2021	2021 (Q3)	-0.04 / -0.05	-0.07	28.57% (+0.02)	―	―
Feb 25, 2022	2021 (Q4)	-0.07 / -0.07	-0.02	-250.00% (-0.05)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

OCGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 08, 2024	$1.08	$0.99	-8.33%
Aug 08, 2024	$1.18	$1.28	+8.47%
May 14, 2024	$1.81	$1.70	-6.08%
Apr 02, 2024	$1.54	$1.38	-10.39%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---